OMX Copenhagen 20
2.020,11
PKT
-307,38
PKT
-13,21
%
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 14.04.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 13.04.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 25.03.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 23.03.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 23.03.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 23.03.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 19.03.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 16.03.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 10.03.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.03.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 04.03.21 | Novo Nordisk Conviction Buy | Goldman Sachs Group Inc. | |
| 22.02.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 18.02.21 | Novo Nordisk Neutral | UBS AG | |
| 16.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 15.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 15.02.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | UBS AG | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 11.02.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 11.02.21 | A.P. Moeller - Maersk A-S (B) overweight | JP Morgan Chase & Co. | |
| 10.02.21 | A.P. Moeller - Maersk A-S (B) buy | Goldman Sachs Group Inc. | |
| 10.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 10.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 09.02.21 | Novo Nordisk buy | Deutsche Bank AG | |
| 08.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 05.02.21 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.02.21 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 04.02.21 | Novo Nordisk overweight | Barclays Capital | |
| 04.02.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 04.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 03.02.21 | Novo Nordisk Outperform | Bernstein Research | |
| 03.02.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 03.02.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 03.02.21 | Novo Nordisk Neutral | UBS AG | |
| 03.02.21 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 26.01.21 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 26.01.21 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 20.01.21 | Novo Nordisk Neutral | Credit Suisse Group | |
| 20.01.21 | Novo Nordisk Underperform | Jefferies & Company Inc. |